Cervical cancer trials

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials is being studied. Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS +9 • Eligibility: Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any…. Goal: The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Johns Hopkins trial is currently recruiting and tests using MRI to guide gynecologic brachytherapy, comparing it with CT planning to see if MRI can better show the tumor and protect nearby healthy tissues. It is for adults with gynecologic cancers (cervix, uterus, vagina, vulva, or urethra) who are eligible for internal brachytherapy, including people who have had prior radiation or chemotherapy. Researchers want to learn if MRI-guided planning lowers the radiation dose to nearby organs and to find safe dose levels that minimize side effects, checking outcomes at 6 months, 1 year, and 2 years after treatment. Key exclusions include uncontrolled illness, very low white blood cell count (ANC < 500), or metal in the head or eyes; participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether using the Headspace mindfulness app before cancer treatment helps people with endometrial cancer needing surgery or cervical cancer treated with chemoradiation. Participants are randomly assigned to use the Headspace app before treatment or not. Eligible participants have a new cancer diagnosis and a smartphone; those who do not speak English, do not have a smartphone, or are already using Headspace are excluded. The goal is to learn whether mindfulness practice before treatment can reduce stress and anxiety and improve the treatment experience.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NYSCF Scientific Discovery Biobank is being studied. Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease +26 • Eligibility: Inclusion Criteria: * Age 30 days or older. * Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control. * Adults…. Goal: The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time. Phase/Status/Sponsor: Unknown phase; RECRUITING; New York Stem Cell Foundation Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests KD01, a recombinant oncolytic adenovirus, to evaluate its safety, tolerability, and anti-tumor activity in gynecologic cancers. - It has Phase I for patients who have failed standard therapy, and Phase II with two groups: cervical cancer patients who want to preserve fertility and endometrial cancer patients with specific features. - The researchers aim to learn how KD01 works in the immune system and its ability to kill tumor cells, while also assessing overall safety. - Key exclusions include serious cardiovascular disease, active infections, autoimmune disorders, HIV/HBV/HCV infection, prior oncolytic therapy, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology is being studied. Conditions: Human Papillomavirus • Eligibility: Inclusion Criteria: -Chronic infected patients defined by: Patients with persistent HPV-HR cytological infection (high risk) (as early as 6 months post-treatment of a cervical or vaginal injury), or…. Goal: The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood. These chronically infected patients could develop multi-site lesions. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital, Toulouse.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors is being studied. Conditions: Hepatocarcinoma, Lung Cancer, Melanoma +7 • Eligibility: Inclusion Criteria: 1. Cytohistological confirmation is required for diagnosis of cancer. 2. Signed informed consent before recruiting. 3. Age above 18 years with estimated survival over 3 months.…. Goal: This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences. Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital of Guangzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is an observational, retrospective study conducted across multiple Italian centers to describe disease characteristics and how locally advanced or recurrent/metastatic cervical cancer is treated. - It includes adult patients (18 years and older) diagnosed with cervical cancer who received any treatment between January 2018 and December 2021. - Researchers will collect data from medical records and enter it into an electronic case report form to describe who is affected and how the disease is managed. - Exclusions include patients participating in pharmacological clinical trials for advanced disease or those who received Pembrolizumab, Olaparib, or Levantinib (or related drugs). - The aim is to provide descriptive information about patient and disease characteristics and treatment patterns in Italy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Development and Management of Registry in Patients With Gynecologic Cancer in Korea is being studied. Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer +2 • Eligibility: Inclusion Criteria: * Female patients 18 years or older * Written informed consent (prospective cohort) * Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer Exclusion Criteria:…. Goal: The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates. Phase/Status/Sponsor: Unknown phase; RECRUITING; Asan Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a longitudinal cohort study to see if cancer treatment accelerates early aging in adolescents and young adults with cancer, by measuring aging markers before therapy and one year later. It includes patients aged 18-39 with a confirmed cancer diagnosis who are about to start systemic therapy with curative intent. The main goal is to see how the senescence marker P16 changes over one year, and it also looks at SASP, vascular markers, and cardiovascular risk factors related to treatment and patient/tumor characteristics. Measurements are taken at two visits and include blood tests and a physical exam (weight, height, waist-hip ratio, blood pressure); key exclusions are inability to understand consent, treatment with immune checkpoint inhibitors or anti-angiogenic therapy, and prior systemic therapy or radiotherapy for another cancer (with limited exceptions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a single-arm, single-center, open clinical study testing GK01, autologous tumor-reactive T cells, given as a cell transfusion to patients with advanced solid tumors. It aims to assess safety and tolerability after GK01 transfusion, and to observe how the cells behave in the body and any early effect on tumors. The trial is for adults aged 18-75 with incurable advanced cancers who have failed standard treatments, including gastric, esophageal, cervical cancers, triple-negative breast cancer, non-small cell lung cancer, and others. It excludes people with active autoimmune disease, immune-related adverse reactions, uncontrolled infections or organ problems, CNS metastases, HIV, hepatitis B or C, pregnancy, or other conditions that make participation unsafe. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology is being studied. Conditions: Gynecologic Disease, Gynecologic Cancer, Endometriosis +5 • Eligibility: Inclusion Criteria: 1. Subject of legal age (according to local legislation) and at least 18 years old 2. Subject (and if applicable her legal representative) having dated and…. Goal: GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva. The study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian/cervical/uterine cancer) and asymptomatic females. Phase/Status/Sponsor: Unknown phase; RECRUITING; ZIWIG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests an oral drug called Q702, a Axl/Mer/CSF1R inhibitor, in combination with pembrolizumab. - It is for adults with advanced or metastatic esophageal, gastric/GEJ, hepatocellular, or cervical cancers that have progressed after anti-PD-1 or anti-PD-L1 therapy. - The study aims to assess safety and look for early signs of effectiveness (preliminary efficacy) in this combination. - Eligibility includes measurable disease, ECOG 0–1, and an expected life expectancy of at least 3 months. - Key exclusions are pregnancy or breastfeeding in women likely to become pregnant, certain drug interactions, recent radiotherapy or a history of radiation pneumonitis, and prior allogeneic transplant.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor +11 • Eligibility: Inclusion Criteria: Patients eligible for inclusion in this study have to meet all of the following criteria: * Patients, 18 years of age or older * Competent and…. Goal: The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centro di Riferimento Oncologico - Aviano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial is testing HPV self-sampling as a way to screen for cervical cancer in Emergency Department patients. It is for cisgender women and transgender/non-binary individuals with a cervix, ages 25 to 65. The goal is to learn whether HPV self-sampling can be deployed in the ED to improve cervical cancer screening among people who are under-screened. Exclusions include past hysterectomy with cervical removal, known HIV infection, and non-English speakers. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether sending HPV self-sampling kits to women’s homes, along with an AI-based, multi-language chatbot decision aid, can improve participation in cervical cancer screening and help manage HPV-positive results. - It targets women aged 30–65 in deprived areas of the Occitanie region who have not had a Pap smear in the last 4 years and did not respond to the first screening invitation. - The study aims to learn if this approach increases the return rate for HPV self-sampling and improves handling of HPV-positive results. - Exclusions include women outside the 30–65 age range, those who had a Pap smear in the past 3 years, those with a hysterectomy including cervix, those who are pregnant, those already scheduled or who have attended screening, those with an ongoing cervical abnormality or treatment, and those who participated in the study pilot.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding stereotactic body radiation therapy (SBRT) to atezolizumab improves the objective response rate (ORR) versus atezolizumab alone in adults with recurrent, persistent, or metastatic cervical cancer. - It is for adults 18 and older with measurable disease from recurrent/persistent/metastatic cervical cancer (including several histologies) and at least two distinct lesions, with consent to biopsy. - The study aims to learn if the combination can increase ORR and provide better disease control than atezolizumab alone. - Key exclusions include known brain metastases, active autoimmune disease (with some allowed exceptions), recent systemic immunosuppressive therapy, and a cancer history within the past two years (with several exceptions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer is being studied. Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 +27 • Eligibility: Inclusion Criteria: * FOCUS GROUP: Women seen at the MD Anderson Oncofertility Clinic and Adolescent and Young Adult Program who are 18-45 years old at the time of…. Goal: This study develops infertility survey among reproductive age women with gynecological and breast cancer. This study aims to learn how women consider whether or not to try to have a baby after surviving cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy is being studied. Conditions: Triple Negative Breast Cancer, Uterine Cervical Cancer, Uterine Corpus Cancer +2 • Eligibility: Inclusion Criteria: 1. Pathologically confirmed diagnosis of clear cell renal cell carcinoma, melanoma, cervical cancer, endometrial cancer or triple negative breast cancer. 2. Patients nnot eligible for radical…. Goal: The aim of the study is to evaluate the response to four schemes of treatment with novel diagnostic tools - Immuno-PET and proteomics as well as standard imaging (magnetic resonsonce imaging and computed tomography). Two fractionation schedules of radiotherapy will be used. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Maria Sklodowska-Curie National Research Institute of Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2 is being studied. Conditions: Breast Cancer, Cervical Cancer • Eligibility: Inclusion Criteria: * Primarily residing in the Gulf Coast \& Lower Rio Grande Valley county areas (or other counties in Texas) * Women 40 years of age and…. Goal: The purpose of this study is to increase early detection and prevention of breast and cervical cancer through education and navigation and to increase breast and cervical cancer screening and Human Papillomavirus (HPV) vaccination in underserved Latinas. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; The University of Texas Health Science Center, Houston.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests online adaptive radiotherapy (oART) with smaller treatment margins for postoperative treatment of endometrial and cervical cancer. - It includes adults who had surgery for these cancers, have no residual tumor at the margins and no distant metastasis, and who will receive cisplatin-based chemotherapy; the treatment delivers 45 or 50.4 Gy to the target volume with reduced margins. - The study aims to determine the clinical efficacy and acute toxicity of the reduced-margin oART, with acute toxicity as the primary endpoint. - Exclusions include prior pelvic radiotherapy, other primary cancers, contraindications to radiotherapy, severe disease, active infection, or active inflammatory bowel disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase II, open-label, single-arm study testing AK104 (Cadonilimab) as a monotherapy for adults with recurrent or metastatic high-grade neuroendocrine carcinoma of the cervix who have already received prior treatment. It aims to estimate progression-free survival at 6 months and to assess response rates, duration of response, safety, and tolerability. The study also looks at whether HPV cell-free DNA in the blood could serve as a marker of response. Key exclusions include brain metastases, active infections, HIV or hepatitis B/C infection, autoimmune disease, and recent or prior immunotherapy or other anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Asian Multicenter Prospective Study of ctDNA Sequencing is being studied. Conditions: Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma +3 • Eligibility: Inclusion Criteria: 1. Age of 18 years or older at registration. 2. Diagnosis of cancer which is targeted by each cohort. 3. Metastatic and/or recurrent disease. Exclusion Criteria:…. Goal: This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types, analytical methods, participating countries, and participating institutions. Phase/Status/Sponsor: Unknown phase; UNKNOWN; National Cancer Center, Japan.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests NGM438 as a standalone treatment and in combination with pembrolizumab for advanced or metastatic solid tumors, to learn about safety and potential effectiveness. It targets adults whose cancer has progressed after other therapies or who could not tolerate them. Eligible participants need adequate bone marrow, kidney, and liver function and a performance status of 0 or 1. They must have recovered from prior treatment side effects to baseline or to CTCAE Grade 1. A key exclusion is prior treatment targeting LAIR1.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gynaecology Exercise and Mindfulness Study is being studied. Conditions: Gynecologic Cancer, Uterus Cancer, Ovary Cancer +3 • Eligibility: Inclusion Criteria: * Diagnosed with stage I-IV gynecologic cancer including endometrial, ovarian, cervical, vaginal, vulva, fallopian tube. * Experiencing fatigue and at screening have a numerical rating score…. Goal: The aim of this study is to explore the feasibility and effectiveness of conducting a mindfulness and home-based walking and strength training program on fatigue, psychological outcomes and quality of life for gynecological cancer survivors. The intervention consists of a 8 week mindfulness and home based walking and strengthening program for gynecology survivors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; University of Ulster.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers is being studied. Conditions: Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms +1 • Eligibility: Inclusion Criteria: * Resistant breast, endometrial, cervix, or ovarian cancer * No active metastasis to the brain * No more than 8 previous regimes of Doxil * Successful…. Goal: Thermal therapy (hyperthermia of heat) can increase the effect of chemotherapy treatments. By itself, thermal therapy can also kill cancer cells. Phase/Status/Sponsor: Unknown phase; UNKNOWN; The University of Texas Health Science Center, Houston.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer is being studied. Conditions: Malignant Melanoma, Pancreatic Cancer, Colon Cancer +1 • Eligibility: Inclusion Criteria: * Advanced melanoma, pancreatic, colon and cervical cancer * At least 1 prior postoperative conventional therapy (chemotherapy, radiation, immunotherapy) * HLA-A1, -A2, -B35 * More than…. Goal: This study evaluates the safety, the immunological response and the clinical outcome of a vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and cervical carcinoma. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Julius-Maximilians University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Questionnaire Study for Gynecological Cancer Survivors is being studied. Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms +3 • Eligibility: Inclusion Criteria: * Female participants diagnosed with gynecologic cancer * Participants between the ages of 20 and 75 years old, inclusive * Participants previously treated for all stages…. Goal: The purpose of this study is to evaluate the quality of life of long-term gynecologic cancer survivors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; U.S. Army Medical Research and Development Command.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Irradiation Modulates the Pharmacokinetics of Anticancer Drugs is being studied. Conditions: Rectal Cancer, Cervical Cancer • Eligibility: Inclusion Criteria: * World Health Organization (WHO) performance status of 0 or 1 * Age 18-80 years * Locally advanced rectal cancer * Locally advanced cervical cancer Exclusion…. Goal: Radiation therapy (RT) is used as an effective local treatment modality to inhibit cell proliferation, induce cell death and suppress tumor growth. To improve the treatment outcome, in terms of both locoregional control and survival, the concurrent use of chemotherapy during radiation therapy (CCRT) is now the standard treatment for various malignancies, especially locally advanced cancers. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Far Eastern Memorial Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 is being studied. Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Agreement to provide fresh or archived tumor tissue sample within 3 years * Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced…. Goal: This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib). Phase/Status/Sponsor: Unknown phase; COMPLETED; Risen (Suzhou) Pharma Tech Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. is being studied. Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer • Eligibility: Inclusion Criteria: * GYN cancer (ovarian, endometrial, or cervical) was biopsy-proven and/or schedule for subsequent surgery based on clinical presentation (imaging, markers) * Age ≥ 18 years. *…. Goal: An important part of staging and deciding the method of treatment is knowing areas of how cancer is involved. Diagnostic imaging is often used to determine the location of the cancer using techniques like nuclear medicine, MRI (magnetic resonance imaging), CT (computerized tomography), and ultrasound. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Bital Savir-Baruch.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan is being studied. Conditions: Cervical Cancers, Endometrial Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Adults aged ≥ 18 years when their clinical data are reviewed 2. Patients who fulfill ONE of the following criteria * Imaging or histological diagnosis…. Goal: Trastuzumab Deruxtecan (T-DXd) is a humanized anti-HER2 monoclonal antibody covalently linked to DXd, which is a topoisomerase 1 inhibitor. T-DXd has been approved for the treatment of HER2-positive breast cancer, HER2-mutated lung cancer, HER2-positive gastric cancer, and HER2-low breast cancer in Taiwan. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients is being studied. Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows: * Phase II: extensive stage small cell lung cancer with progression…. Goal: The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. \*\*The Phase 1b portion of the study is now complete\*\*. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cancer Research and Biostatistics Clinical Trials Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase I trial tests an intrapleural gene therapy called BG00001, which delivers the interferon-beta gene into the pleural space to treat malignant pleural mesothelioma or malignant pleural effusions. It is for adults 18 and older whose disease has progressed after standard therapy and whose pleural space can be accessed with a chest catheter. The study aims to find a safe dose, determine the maximum tolerated dose, assess gene transfer and interferon-beta expression, monitor immune responses, and look for early signs of tumor effect. Key exclusions include HIV positivity, active brain metastases (unless previously treated with no active growth), ongoing immunosuppressive therapy, pregnancy, and other active cancers within the past 5 years (with limited exceptions for certain skin cancers or successfully treated localized bladder or prostate cancer).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether ondansetron works better for preventing vomiting when given with dexamethasone versus with a placebo in cancer patients receiving radiation therapy to the upper abdomen. - It is a randomized, double-blind, placebo-controlled, multicenter study. - It looks at how well the two regimens prevent vomiting and nausea, their side effects, and impact on quality of life. - Eligible participants are people aged 16 or older with cancer planned for upper abdominal radiotherapy (at least 2,000 cGy in 15+ fractions) who have not had significant vomiting recently; major exclusions include liver problems, active peptic ulcers, concurrent cytotoxic therapy or other steroids, and a history of adverse reactions to antiemetic drugs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers is being studied. Conditions: Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer +2 • Eligibility: -INCLUSION CRITERIA: 1. Measurable metastatic or locally advanced refractory/recurrent malignancies that are human papilloma virus 16 (HPV-16) or human papilloma virus 18 (HPV-18) high HPV positive by in…. Goal: Background: The human papillomavirus (HPV) can cause a number of cancers, including cervical and throat cancers. The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Understanding the Value of Community Vital Signs in Primary Care is being studied. Conditions: Colon Cancer, Breast Cancer, Cervical Cancer +2 • Eligibility: Inclusion Criteria: * Aims 1a and 1b: Patients seen at one of the 12 study practices * Aims 2 and 3: Clinicians at one of the 12 study…. Goal: Social determinants of health (e.g. the income, education, and environment of patients) may exert greater influence on health outcomes than traditional clinical factors (e.g. Phase/Status/Sponsor: Unknown phase; COMPLETED; Virginia Commonwealth University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers is being studied. Conditions: Non-ovarian Gynecological Cancers • Eligibility: Inclusion Criteria: * ≥Age 18 years (no upper age limit) * Diagnosis of cervical, vaginal, vulvar, or endometrial cancer with either pelvic radiotherapy or chemoradiotherapy planned as part…. Goal: The purpose of this study is to investigate the association between the Independent Activities of Daily Living (I-ADL) component of the Comprehensive Geriatric Assessment (CGA) and poor tolerance to radiation treatment in older and younger patients with non-ovarian gynecological cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Internet-based System for Cancer Patients to Self-report Toxicity is being studied. Conditions: Cervical Cancer, Lung Cancer, Prostate Cancer +4 • Eligibility: Inclusion Criteria: * Age \>18 years * Diagnosis of gynecologic (ovarian; cervical; uterine; primary peritoneal), lung (non-small cell; small cell), gastrointestinal (colorectal, rectal, gastric, esophageal, GI neuroendocrine, small…. Goal: Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath. These symptoms may be due to the cancer itself, or due to treatments like chemotherapy drugs or radiation therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed cancer, including, but not limited to, the following: * Melanoma * Breast cancer * Invasive squamous cell cancer * Other cancers…. Goal: RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. Phase/Status/Sponsor: Unknown phase; COMPLETED; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers is being studied. Conditions: Cervical Cancer, Vulvar Cancer • Eligibility: Inclusion Criteria: * Patients with histologically proven gynecological cancers * Patients with FIGO IA2 and IB1 cervical cancers * Cervical cancer patients will be scheduled for radical hysterectomy…. Goal: Nodal staging is a key-step in pre-treatment assessment of gynecological cancers. In recent years, lymphatic mapping and sentinel lymphadenectomy (LM/SL) as a minimally invasive pelvic lymph nodes staging has been successfully evaluated in women with early stage of vulvar cancer, cervical cancer, and endometrial cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Therapy in Treating Patients With Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven CEA expressing adenocarcinoma * Serum CEA levels greater than 10 ng/mL * Failed standard therapy * Measurable disease PATIENT CHARACTERISTICS: Age: * 18…. Goal: RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have cancer that has not responded to previous therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Roger Williams Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed advanced malignancy involving the peritoneal cavity, excluding leukemia and lymphoma Patients with ovarian cancer must have received prior standard therapy Predominantly small tumor metastases…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced cancer of the peritoneal cavity. Phase/Status/Sponsor: Unknown phase; COMPLETED; NYU Langone Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer is being studied. Conditions: Neoplasms • Eligibility: Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid…. Goal: Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer Phase/Status/Sponsor: Unknown phase; COMPLETED; Vincerx Pharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene is being studied. Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification +41 • Eligibility: Inclusion Criteria: Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male…. Goal: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. Phase/Status/Sponsor: Unknown phase; COMPLETED; Klus Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers is being studied. Conditions: Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter +81 • Eligibility: Inclusion Criteria: * Primary family caregivers of cancer patients with gastrointestinal (colorectal, pancreatic, gastric), gynecologic, urinary or lung cancers who are entering the City of Hope for treatment…. Goal: This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Cervical cancer (stage I, II, or III) patients who have completed definitive treatment at least 2 months earlier and who were diagnosed between 9 and…. Goal: The purpose of the study is to: 1. Test the efficacy of psychosocial telephone counseling (PTC) for cervical cancer survivors, compared to usual care. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, Irvine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children is being studied. Conditions: Breast Cancer, Cervical Cancer, Colon Cancer +5 • Eligibility: Inclusion Criteria: * Parents will be eligible if they have an initial diagnosis of non-metastatic cancer of any type (stage 0-3), including melanoma, colorectal, cervical, leukemia, lymphoma or…. Goal: This pilot clinical trial studies the feasibility of a telephone-based educational intervention in improving communication between patients with stage 0-III cancer and their children. An educational program delivered by telephone may help parents talk with their school-age child about their cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Washington.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) is being studied. Conditions: Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer +85 • Eligibility: Inclusion Criteria: * Part I (closed to accrual as of 6/8/2007) * Histologically confirmed solid tumor that is metastatic or unresectable for which standard curative measures do not…. Goal: This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tested the combination of interleukin-12 and trastuzumab in people with HER2/neu-overexpressing cancers that have not responded to prior treatment. It was a Phase I dose-escalation trial to find the highest IL-12 dose that could be given safely with trastuzumab and to assess safety. The trial also looked at immune effects, including tumor gene expression, natural killer cell activity, and serum interferon gamma levels. Participants needed measurable disease from HER2-overexpressing cancer and adequate organ function, with a life expectancy of at least 6 months. Exclusions included brain metastases, significant cardiovascular disease, pregnancy, HIV or hepatitis B infection, recent cancer therapies, and prior treatment with Herceptin; the study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tested INCB099280 to see if it is safe and tolerable, how the drug behaves in the body, and whether there is any early anti-tumor activity. It was for adults with advanced solid tumors that cannot be cured with surgery or standard treatments and that have measurable disease. The study aimed to learn about safety, pharmacokinetics, pharmacodynamics, and any early clinical benefit of the drug. Key exclusions included active infections, significant heart disease, untreated or progressing brain metastases, HIV or hepatitis B/C, prior anti-PD-L1 therapy, and recent systemic anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors is being studied. Conditions: Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma +6 • Eligibility: Key Inclusion Criteria: * Have a histologically or pathologically documented, locally-advanced or metastatic solid tumor for which standard curative measures do not exist or are no longer effective…. Goal: To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01). Phase/Status/Sponsor: Unknown phase; TERMINATED; Turnstone Biologics, Corp..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) is being studied. Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma +13 • Eligibility: Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following:…. Goal: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S is being studied. Conditions: Astrocytoma, Brain Cancer, Brain Metastases +20 • Eligibility: Inclusion Criteria: 1. Male or female participants aged ≥18 years at the time of informed consent. 2. Adequate Bone Marrow Function 3. Adequate renal function 4. Adequate Liver…. Goal: This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Quadriga Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- Milademetan is being tested in adults with advanced or metastatic solid tumors that have wild-type TP53 and MDM2 amplification (copy number ≥ 8) and who are refractory or intolerant to standard therapy. - It is a multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in this biomarker-defined group. - About 65 patients will be enrolled and treated until disease progression, unacceptable toxicity, or other criteria, with follow-up for progression and survival. - Key exclusions include prior MDM2 inhibitors, certain brain tumors or untreated brain metastases, active HIV or hepatitis infections, and significant cardiovascular disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LITT and Pembrolizumab in Recurrent Brain Metastasis is being studied. Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) +12 • Eligibility: INCLUSION CRITERIA 1. Histologic confirmation of primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor 2. At least one metastatic lesion has had prior SRS.…. Goal: This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS). Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive is being studied. Conditions: Breast Cancer, Cervical Cancer, Renal Cancer +2 • Eligibility: * INCLUSION CRITERIA: 1. Metastatic or locally advanced refractory/recurrent cancer that expresses MAGE-A3 as assessed by one of the following methods: reverse transcription polymerase chain reaction (RT-PCR) on…. Goal: Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms is being studied. Conditions: Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer +7 • Eligibility: Inclusion Criteria: * Histologically proven, locally advanced unresectable or metastatic solid tumors (or hematologic malignancies, Cohort Expansion only) for whom no approved therapy with demonstrated clinical benefit is…. Goal: The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed. Phase/Status/Sponsor: Unknown phase; COMPLETED; MacroGenics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I Clinical Trial of Bevacizumab Injection is being studied. Conditions: Rectal Cancer, Lung Cancer, Ovarian Cancer +2 • Eligibility: Inclusion Criteria: * 1 Fully understand the purpose of the test, and basically understand the pharmacological effects and possible adverse reactions of the research drugs; Voluntarily sign written…. Goal: Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs. Its mechanism is to prevent VEGF from binding to its natural receptor VEGFR, inhibit the proliferation and activation of vascular endothelial cells, and play an anti angiogenesis and anti-tumor role by binding with VEGF. Phase/Status/Sponsor: Unknown phase; COMPLETED; Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility is being studied. Conditions: Cervical Cancer • Eligibility: Inclusion Criteria: * Stage Ib1 cervical cancer measuring ≥2 - ≤4 cm on physical examination and imaging in any direction * Histologic type: squamous cell carcinoma (SCC), adeno…. Goal: If no metastases are observed, patients will start a short protocol of four courses of weekly neo-adjuvant chemotherapy (12 weeks). If response to chemotherapy results in a tumor of less than 2 cm, cervical conisation will be performed. Phase/Status/Sponsor: Unknown phase; TERMINATED; The Netherlands Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors is being studied. Conditions: Melanoma, Breast Cancer, Merkel Cell Carcinoma +10 • Eligibility: Inclusion Criteria: 1. Age ≥18 years. 2. Advanced solid tumor with measurable disease. 3. Subject must have failed or have contraindication to standard therapies. 4. For Cohort 1,…. Goal: This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy. Phase/Status/Sponsor: Unknown phase; TERMINATED; Craig L Slingluff, Jr.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer is being studied. Conditions: Gynecologic Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Histologically confirmed primary cancer of the uterine cervix, uterine corpus, ovary, and fallopian tube * FIGO stage Cervical cancer: FIOG stage IA2-IIA2 Uterine cancer: FIGO…. Goal: To compare the incidence of lymphocele and lymphatic ascites between patient who use versus who do not use FloSeal during lymph node dissection Phase/Status/Sponsor: Unknown phase; COMPLETED; Asan Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes is being studied. Conditions: Solid Tumor • Eligibility: Key Inclusion Criteria: * Unresectable, locally advanced or metastatic solid tumor and relapsed/progressive disease * Measurable disease per RECIST v1.1 or modified RECIST v1.1 and PCWG3 (for prostate…. Goal: A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes. Phase/Status/Sponsor: Unknown phase; TERMINATED; pharmaand GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested an imaging agent called 89Zr-girentuximab to detect CAIX expression in solid tumors using PET/CT. - It was for adults 18 and older with a proven solid tumor, including cancers such as cervical, colorectal, esophageal, gastric, brain tumors (GBM), head and neck cancers, lung cancers, ovarian cancer, pancreatic cancer, soft tissue sarcoma, mesothelioma, and certain VHL-related lesions. - Researchers aimed to learn how well this PET imaging can identify CAIX on tumors and what it reveals about CAIX expression across cancer types. - Key exclusions included recent radionuclide exposure, prior CAIX-targeting treatments, pregnancy, significant kidney impairment (GFR ≤45), and other major illnesses or allergy to the imaging agents. - Status: terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ultrasound and Photoacoustic Imaging for Cervical Cancer is being studied. Conditions: Cervical Cancer, Cancer of the Cervix • Eligibility: * Diagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapy. * At least 18 years of age. * Not pregnant…. Goal: The investigators have developed co-registered transvaginal photoacoustic and ultrasound (US) imaging techniques that allow them to visualize ovarian tumor structure and functional changes simultaneously, which may potentially reveal early tumor angiogenesis development or residual tumors after systemic treatment that is not available by US alone. The ability to detect early angiogenesis changes, as well as tumor morphology changes using a non-invasive imaging modality will greatly enhance the care for patients. Phase/Status/Sponsor: Unknown phase; TERMINATED; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer is being studied. Conditions: Cervical Cancer • Eligibility: Inclusion Criteria: * Patients must have IB2 and IIA tumors greater than 4 cm in diameter, IIB, IIIB without hydronephrosis or non-functioning kidney, and IVA without invasion to…. Goal: This trial is designed to study the safety and efficacy of the combination of carboplatin, bevacizumab, and pelvic radiation therapy. Rationale for substituting cisplatin with carboplatin: Five landmark trials in cervical cancer prompted the National Cancer Institute in February of 1999 to issue a clinical announcement stating that "strong consideration should be given to adding concurrent chemotherapy in the treatment of invasive cervical cancer". Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Leo W. Jenkins Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.